| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Total revenues net | 26,043 | 27,165 | 24,960 | |
| Costs related to patient fee revenue | 4,929 | 4,901 | 4,646 | |
| Costs related to product sales | 324 | 319 | 221 | |
| Costs related to service and repair fees | 1,059 | 1,182 | 1,091 | |
| Costs related to service and repair fees related parties | 8 | 58 | 67 | |
| Costs related to management and other fees | 7,812 | 6,897 | 7,319 | |
| Costs related to management and other fees related medical practices | 1,464 | 1,714 | 1,573 | |
| Research and development | 440 | 441 | 307 | |
| Selling, general and administrative expenses | 6,813 | 7,991 | 5,130 | |
| Total costs and expenses | 22,849 | 23,503 | 20,354 | |
| Income from operations | 3,194 | 3,662 | 4,606 | |
| Interest expense | 1 | 7 | 8 | |
| Interest income related party | 12 | 13 | 13 | |
| Investment income | 474 | 463 | 639 | |
| Other income (expense) | 3 | -1 | -1 | |
| Income before provision for income taxes and noncontrolling interests | 3,682 | 4,130 | 5,249 | |
| Provision for income taxes | 1,012 | 1,006 | 1,249 | |
| Consolidated net income | 2,670 | 3,124 | 4,000 | |
| Net income noncontrolling interests | 406 | 618 | 865 | |
| Net income attributable to fonar | 2,264 | 2,506 | 3,135 | |
| Basic eps | - | 0.38 | 0.47 | |
| Diluted eps | - | 0.37 | 0.46 | |
| Basic average shares | - | 6,865,000 | 6,304,000 | |
| Diluted average shares | - | 6,296,000 | 6,432,000 | |
| Basic net income per common share available to common stockholders | 0.34 | - | - | |
| Diluted net income per common share available to common stockholders | 0.34 | - | - | |
| Weighted average basic shares outstanding - common stockholders | 6,169,000 | - | - | |
| Weighted average diluted shares outstanding - common stockholders | 6,296,000 | - | - | |
FONAR CORP (FONR)
FONAR CORP (FONR)